



June 1, 2017

Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company's Chairman and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:

- | Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 9:30 a.m. ET
- | JMP Securities 2017 Life Science Conference on Tuesday, June 20, 2017 at 11:30 a.m. ET

The presentations will be webcast live from the investor relations section of the Adamas website at <http://ir.adamaspharma.com/events.cfm>. Archived versions of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson's disease, multiple sclerosis, epilepsy, and Alzheimer's disease. Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response. The company's most advanced product candidate, ADS-5102, is a high-dose amantadine, taken once daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease and for the treatment of walking impairment in people with multiple sclerosis. A New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease is under review by the FDA with a PDUFA date of August 24, 2017. Adamas is exploring other indications for further development of ADS-5102. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas' licensed assets, are currently marketed by Allergan under the brand names NAMENDA XR[®] and NAMZARIC[®], and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.

NAMENDA XR[®] and NAMZARIC[®] are trademarks of Merz Pharma GmbH & Co. KGaA.

Contact:

Martin Forrest

Vice President, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3528

ir@adamaspharma.com

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

 Primary Logo

Source: Adamas Pharmaceuticals, Inc.

News Provided by Acquire Media